US won't release AstraZeneca's vaccine until sure about safety: Official

The US FDA will not release AstraZeneca's coronavirus vaccine for export to other countries until it is sure the doses have been manufactured to US quality standards and will be safe and effective

Topics
AstraZeneca | United States | Coronavirus Vaccine

ANI  |  US 

AstraZeneca's Covid-19 vaccine | Photo: Bloomberg
AstraZeneca's Covid-19 vaccine | Photo: Bloomberg

The US Food and Drug Administration will not release AstraZeneca's for export to other countries until it is sure the doses have been manufactured to US quality standards and will be safe and effective, a government official told CNN on Thursday.

According to CNN, The White House said on Monday it would ship doses of vaccine to other countries, including India, after a safety review by the FDA.

has yet to apply for emergency use authorisation (EUA) in the US, but the company has been making tens of millions of doses in the US in the expectation that it will apply for and receive EUA eventually.

Many other countries have been clamouring for vaccine and international groups have criticized the US for buying up vaccine doses while billions of people around the world go without.

The safety review will be thorough, a government official with knowledge of the process who was not authorized to speak on the subject and requested anonymity told CNN.

While a EUA is not needed to export vaccines, the official said, the US would not export any vaccine that did not meet US safety, efficacy and manufacturing quality standards.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on AstraZeneca
First Published: Fri, April 30 2021. 12:23 IST
RECOMMENDED FOR YOU